Maxacalcitol Explained

Drug Name:	Maxacalcitol
Tradename:	Oxarol
Routes Of Administration:	IV or topical
Legal Status:	Rx-only
Synonyms:	22-Oxacalcitriol; OCT
Cas Number:	103909-75-7
Chemspiderid:	4911262
Chebi:	31801
Chembl:	333950
Iuphar Ligand:	2784
Pubchem:	6398761
Unii:	N2UJM5NBF6
Drugbank:	DB06272
Iupac Name:	(1R,3S,5Z)-5-[(2''E'')-2-[(1''S'',3a''S'',7a''S'')-1-[(1''S'')-1-(3-Hydroxy-3-methylbutoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
C:	26
H:	42
O:	4
Stdinchi:	1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1
Stdinchikey:	DTXXSJZBSTYZKE-ZDQKKZTESA-N
Smiles:	C[C@@H]([C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C)OCCC(C)(C)O

Maxacalcitol (trade name Oxarol) is a vitamin D₃ analog and vitamin D receptor activator (VDRA).^[1] As a pharmaceutical drug, it is used as an injection to treat secondary hyperparathyroidism resulting from hemodialysis and as a topical ointment for psoriasis.^[2]

It was approved for use in Japan in 2010^[3] and in Taiwan in 2018.^[4]

Notes and References

Mizobuchi M, Ogata H . Clinical uses of 22-oxacalcitriol . Current Vascular Pharmacology . 12 . 2 . 324–328 . March 2014 . 23713875 . 10.2174/15701611113119990023 .
Web site: Maxacalcitol . Inxight Drugs . National Center for Advancing Translational Sciences, U.S. National Institutes of Health .
Web site: Maxacalcitol . D01098 . New Drug Approvals in Japan . Kyoto Encyclopedia of Genes and Genomes .
Fukazawa-Shinotsuka M, Saito T, Abe M, Iida S, Wang IT, Terao K, Chen HH, Liu MC . Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis . Drug Research . 72 . 1 . 23–33 . January 2022 . 34488237 . 10.1055/a-1581-7609 .